Is Polymyalgia Rheumatica an Inflammatory Condition?

Polymyalgia rheumatica is one of the most common inflammatory rheumatic diseases in older adults, yet its name is a little misleading. "Polymyalgia" translates to "many muscle pains," which suggests a muscle problem. In reality, the muscles themselves are largely innocent. The pain and stiffness come from inflammation in the structures around the joints, particularly the bursae and the synovial lining of the shoulders and hips. In that sense, PMR belongs firmly in the family of inflammatory conditions, and its behavior in the bloodstream reflects that.

What Is Polymyalgia Rheumatica?

PMR is a syndrome defined by a fairly distinctive pattern of symptoms in a specific age group. It almost never appears before age 50, and the average person with PMR is in their early 70s. Women are affected roughly two to three times more often than men, and it is more common in people of Northern European ancestry.

The hallmark is symmetry and stiffness. The classic presentation is new, bilateral aching in the shoulders, and often the hips and neck, that is dramatically worse in the morning. Morning stiffness lasting more than 45 minutes is one of the more specific features. Many people describe struggling to lift their arms to comb their hair or to get out of a chair or car. Symptoms frequently come on quickly, sometimes almost overnight, which is unusual for a musculoskeletal complaint and is one reason it stands out to clinicians.

It often brings whole-body signs of inflammation. Beyond the joints, PMR can produce the general signals of a body mounting an inflammatory response: low-grade fever, fatigue, loss of appetite, malaise, and sometimes unintended weight loss. These constitutional symptoms are part of why PMR is understood as a systemic inflammatory condition rather than a localized wear-and-tear problem.

Why Polymyalgia Rheumatica Counts as Inflammatory

The label "inflammatory" is not a loose description here. It reflects what is actually happening in the tissues and in the blood.

The inflammation is in the tissues around the joints. Imaging studies have reshaped how PMR is understood. Ultrasound and MRI reveal that the pain corresponds to inflammation of the bursae and tendon sheaths, most notably subacromial and subdeltoid bursitis at the shoulder and similar changes at the hip. According to a systematic review of PMR and giant cell arteritis published in JAMA in 2016, ultrasound detects bilateral subdeltoid bursitis in roughly 69 percent of people with PMR, which helps explain why the shoulder girdle is so consistently involved (Buttgereit et al., 2016).

The signaling molecule interleukin-6 is a central driver. PMR is associated with high activity of the pro-inflammatory cytokine interleukin-6 (IL-6). IL-6 is also the main signal that tells the liver to produce C-reactive protein, which is exactly why CRP rises in PMR. This link between the cytokine driving the disease and the marker measured in the blood is part of what makes inflammatory markers so useful for tracking PMR. It also explains why medications that block IL-6 can lower CRP in these patients, which in turn complicates how CRP is interpreted during that specific treatment.

The blood work reflects systemic inflammation. Elevated inflammatory markers are one of the most consistent laboratory findings in PMR. The same 2016 JAMA review reported that elevated inflammatory markers are present in more than 90 percent of people with PMR and giant cell arteritis (Buttgereit et al., 2016). That is a strikingly high proportion, and it is why a normal CRP and ESR make the diagnosis less likely, though not impossible.

How CRP and ESR Fit Into Diagnosis

There is no single test that confirms PMR. Instead, clinicians combine the clinical picture with inflammatory markers and, increasingly, imaging. Inflammatory markers do a lot of the heavy lifting.

Elevated markers are part of the formal criteria. In 2012, the European League Against Rheumatism and the American College of Rheumatology published provisional classification criteria for PMR. The scoring system applies to people aged 50 and older with new bilateral shoulder pain and an elevated CRP and/or ESR, and then adds points for features such as morning stiffness lasting more than 45 minutes, new hip involvement, and the absence of rheumatoid factor and anti-CCP antibodies. A score of 4 or higher had 68 percent sensitivity and 78 percent specificity for distinguishing PMR from conditions that mimic it (Dasgupta et al., 2012). Notably, an elevated inflammatory marker is treated as an entry requirement, which underscores how tightly PMR is tied to measurable inflammation.

CRP and ESR give complementary information. Both markers rise with inflammation, but they behave differently over time. CRP climbs and falls quickly, often within a day or two, making it responsive to change. ESR moves more slowly and is influenced by age, sex, and anemia. Because they capture slightly different things, many clinicians look at both, and the two are the subject of their own comparison in our guide to CRP versus ESR.

Markers help rule mimics in or out. Several conditions can imitate PMR, including rheumatoid arthritis in older adults, thyroid disease, and shoulder problems like rotator cuff disease. Inflammatory markers, along with tests for rheumatoid factor and anti-CCP antibodies, help sort these out. This is also why PMR is not diagnosed on symptoms alone: the pattern of inflammation in the blood is part of the evidence.

The Link to Giant Cell Arteritis

PMR does not exist in isolation. It is closely related to giant cell arteritis (GCA), an inflammatory disease of medium and large arteries that also occurs almost exclusively in people over 50. The two conditions overlap substantially: a meaningful share of people with PMR have features of GCA, and many people with GCA have PMR-type symptoms.

The distinction matters because GCA can be serious. When the inflammation involves the arteries that supply the eyes, it can threaten vision, which is why new headache, scalp tenderness, jaw pain when chewing, or visual changes in someone with PMR are treated as urgent. GCA is a form of vasculitis, and both conditions typically produce elevated CRP and ESR, though the levels in GCA are often higher. The shared inflammatory biology of PMR and GCA is one of the clearest illustrations that PMR is an inflammatory disease rather than a mechanical one.

How Inflammation Is Tracked During Treatment

PMR is notable for how well it responds to treatment, and inflammatory markers are woven through that process from start to finish.

The response to glucocorticoids is fast and telling. Low-dose glucocorticoids, typically prednisone in the range of 12.5 to 25 milligrams per day, are the mainstay of treatment, and the improvement is often dramatic within a few days (Buttgereit et al., 2016). As symptoms settle, CRP and ESR usually fall in parallel. That rapid, marker-confirmed response is so characteristic that a poor response prompts clinicians to reconsider the diagnosis.

Markers guide tapering and catch relapses. Most people need treatment for one to two years or longer, and the dose is tapered slowly. Inflammatory markers help judge whether the taper is going too fast. Researchers have even built formal tools around this: the PMR Activity Score incorporates the CRP value alongside symptoms and stiffness to quantify disease activity, and alternative versions have been developed for situations where CRP is unavailable or has been artificially lowered by IL-6-blocking therapy (Devauchelle-Pensec et al., 2018). A rise in CRP as the dose comes down can signal a flare before symptoms fully return.

Modern management aims at sustained remission. Treat-to-target recommendations for PMR and GCA, published in 2024, frame the goal as achieving and maintaining remission while minimizing the harms of long-term steroids, with disease activity assessed using both symptoms and inflammatory markers (Dejaco et al., 2024). In practice, that makes tracking inflammation over months a routine part of living with PMR, not a one-time event.

Lifestyle, Inflammation, and Living With PMR

PMR is a medical condition that requires medical treatment, and no lifestyle change substitutes for the care a rheumatologist provides. That said, the same general principles that support a lower inflammatory baseline in the wider population are reasonable companions to treatment, and some carry extra weight because long-term steroids have their own downsides.

Protecting bone and muscle matters. Because glucocorticoids can thin bone and because inactivity from pain can erode muscle, gentle movement, adequate protein, and attention to bone health are commonly emphasized. Weight-bearing activity, within the limits of comfort, helps preserve function during the months of treatment.

A broadly anti-inflammatory pattern is sensible. A diet rich in vegetables, fruit, fiber, and omega-3 sources, along with good sleep and stress management, supports overall inflammatory balance. These steps do not treat PMR, but they align with the same biology and may help with the general fatigue and malaise that accompany an inflammatory state. Our overview of an anti-inflammatory diet covers the broader evidence.

Watch for warning signs. Anyone with PMR should know the symptoms of giant cell arteritis and seek care promptly if they appear. Because both conditions are driven by inflammation, changes in how you feel are worth taking seriously rather than waiting out.

Where CRP Tracking Fits Into a Wellness Routine

Because PMR is so closely tied to measurable inflammation, C-reactive protein is one of the most practical numbers for understanding what an inflammatory state looks like in the body. CRP reflects the same IL-6-driven signaling that defines PMR, which is why it rises when inflammation is active and falls when it settles.

Sensa is a general wellness tool that makes checking CRP at home simple, without a needle or a clinic visit, so a measurement becomes a routine data point rather than a rare event. For someone interested in inflammation as part of a healthy lifestyle, watching a CRP trend over time offers tangible feedback on how the body is responding to sleep, activity, and diet. It is important to be clear about scope: Sensa does not diagnose, treat, or monitor PMR or any other disease, and it is not a substitute for the inflammatory-marker testing and clinical judgment that PMR management requires. Anyone with new, persistent aching and stiffness in the shoulders and hips, especially over age 50, should see a healthcare provider, who can order the appropriate tests and interpret them in context. CRP is a window into inflammation, and understanding that window is where at-home tracking can add value to a broader wellness picture.

Polymyalgia rheumatica is a clear example of how inflammation, symptoms, and a simple blood marker line up. The aching is real, the inflammation behind it is measurable, and CRP is one of the clearest ways to see it.

Sources

• Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA, 2016;315(22):2442-58. pubmed.ncbi.nlm.nih.gov/27299619
• Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a EULAR/ACR collaborative initiative. Annals of the Rheumatic Diseases, 2012;71(4):484-92. pubmed.ncbi.nlm.nih.gov/22388996
• Devauchelle-Pensec V, Saraux L, Berthelot JM, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology (Oxford), 2018;57(4):666-670. pubmed.ncbi.nlm.nih.gov/29346621
• Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2024;83(1):48-57. pubmed.ncbi.nlm.nih.gov/36828585

Frequently Asked Questions

Is polymyalgia rheumatica an inflammatory disease?

Yes. Polymyalgia rheumatica is an inflammatory rheumatic condition. The pain and stiffness come from inflammation of the bursae and synovial tissues around the shoulders and hips, not from the muscles themselves, and it is usually accompanied by elevated inflammatory markers in the blood such as CRP and ESR.

Does polymyalgia rheumatica raise CRP?

In most cases, yes. PMR is associated with high activity of the cytokine interleukin-6, which signals the liver to make C-reactive protein, so CRP is typically elevated. A 2016 JAMA systematic review found that more than 90 percent of people with PMR and giant cell arteritis have elevated inflammatory markers, and CRP usually falls once treatment brings the inflammation under control.

Can you have polymyalgia rheumatica with normal CRP?

It is uncommon but possible. Elevated CRP and/or ESR is part of the standard classification criteria and is present in the large majority of cases, so normal markers make PMR less likely. A small number of people can have PMR with normal or only mildly raised markers, which is why diagnosis relies on the whole clinical picture rather than blood tests alone.

Is polymyalgia rheumatica the same as rheumatoid arthritis?

No. Both are inflammatory and both can raise CRP and ESR, but they differ. PMR centers on the shoulder and hip girdles, begins after age 50, lacks the joint erosion seen in rheumatoid arthritis, and typically tests negative for rheumatoid factor and anti-CCP antibodies. Because the two can look similar early on, doctors use antibody tests and the pattern of joint involvement to tell them apart.